Forecast for injectable agents: more and higher cost












Twenty injectable drugs accounted for two-thirds of the total injectable costs, excluding chemotherapy agents and vaccines, at a representative HMO with two million covered lives. That is typical, says Don Dindak of Bioscrip Injectables. "Injectable agents are 8 percent to 15 percent of the total drug bill, depending on plan demographics," says Dindak. "If you compare the costs of injectable agents on a per-patient basis compared to a PBM-- regular card and mail programs — the average cost per month is $1,000 for a patient who needs a top-20 injectable drug. That is eight to ten times what a patient in a PBM spends."

And the number of injectable agents and the cost is just beginning to grow, says Dindak. "There are about 90 to 95 injectable agents available, but there are about 350 agents in the pipeline, and 40 percent are related to cancer. This increase will add significantly to the drug bill. And the cost of injectable agents is growing at a rate of 20 percent to 40 percent, about twice as fast as regular drugs are growing," he says.

The top 20 injectable drug costs in a representative HMO

Total: $35 million

SOURCE: BIOSCRIP INJECTABLES

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.

UP NEXT

Managed Care
By Peter Wehrwein
Managed Care
By Howard Wolinsky